Product Information
METHYLERGONOVINE 0.2 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $4.4972 per EA under NDC 16571073528. Its NADAC has been published 198 times since Dec 21, 2022.
FDA first approved this application on Jan 15, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.2 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571073528
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLERGONOVINE MALEATEApproval Type
Generic (ANDA)
FDA Application
ANDA211919FDA Approved
1/15/2021
TE Code
AB
On Market Since
1/15/2021
Pharmacological Classes
Price Statistics
The NADAC for METHYLERGONOVINE 0.2 MG TABLET has been published 198 times since Dec 21, 2022, and over the history we have for it it has declined 51.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.4972 per EA |
|---|---|
| All-time high | $14.5746 (Jan 10, 2024) |
| All-time low | $4.3506 (Aug 19, 2026) |
| 52-week high | $5.7474 |
| 52-week low | $4.3506 |
| Median price | $6.4823 |
| Average price | $7.9516 |
| Largest weekly change | -34.7% (Feb 21, 2024) |
| Weeks tracked | 198 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylergonovine Maleate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Ergot Derivative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLERGONOVINE 0.2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METHYLERGONOVINE 0.2 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $4.4972 per EA (NDC 16571073528), effective Sep 30, 2026.
How has the price of METHYLERGONOVINE 0.2 MG TABLET changed over time?
Over the history we have for it, the NADAC for METHYLERGONOVINE 0.2 MG TABLET has declined 51.0%. It has been tracked across 198 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for METHYLERGONOVINE 0.2 MG TABLET?
Since Dec 21, 2022, the NADAC for METHYLERGONOVINE 0.2 MG TABLET has ranged from a low of $4.3506 (Aug 19, 2026) to a high of $14.5746 (Jan 10, 2024), with a median of $6.4823 per EA.
Are there cheaper alternatives to METHYLERGONOVINE 0.2 MG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as METHYLERGONOVINE 0.2 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures METHYLERGONOVINE 0.2 MG TABLET?
METHYLERGONOVINE 0.2 MG TABLET (NDC 16571073528) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.